Elevance Health, Inc. — Annual Report FY2026
Quality Scores
AI Summary
Elevance Health (formerly Anthem) has undergone a massive scaling phase, with revenue growing from $21.71B in 2016 to nearly $199.13B in 2025. While the top-line expansion is extraordinary, particularly the jump in 2021, the bottom-line profitability and cash flow generation have not scaled with equal velocity. Net income margins have compressed significantly, and the company is currently navigating a period of declining earnings despite record revenues. The transition from a regional Blue Cross Blue Shield provider to a diversified health services giant is evident, but the capital-intensive…
Key Changes
The 10-year business evolution of Elevance Health is characterized by its strategic transformation from a traditional health insurer (Anthem) to an integrated health services leader (Elevance). In the first half of the decade, the company focused on Medicaid expansion and Medicare Advantage growth to offset commercial volatility. The 2021-2022 rebranding marked a pivotal shift, consolidating disparate health services under the Carelon brand, which provides pharmacy, behavioral, and digital health services. This move toward 'whole health' has allowed the company to participate in the lucrative PBM space and reduce its dependence on underwriting spread. Geographic expansion through acquisitions, such as the Integra Managed Care deal, and digital transformation initiatives have improved…
Management Commentary
Management successfully navigated the rebranding from Anthem to Elevance Health, signaling a shift toward a holistic health company. They have demonstrated an ability to manage a vast, regulated enterprise and maintain a consistent dividend policy. However, the recent 2024-2025 guidance and delivery show signs of strain, with net income declining despite a $22B increase in revenue. Communication regarding the 'medical loss ratio' and Medicare Advantage headwinds has been transparent, but the efficiency of execution in the post-pandemic environment is under scrutiny. The focus on 'whole health' is a clear vision, but the financial translation of that vision into shareholder alpha has stalled recently.
Financial Highlights
The financial trajectory is bifurcated by a structural shift in 2021 where revenue grew over 300%, likely reflecting major acquisitions or accounting consolidation of Carelon and Wellpoint services. Despite revenue growing at a 10-year CAGR of approximately 28%, net income has exhibited volatility, with 2025 earnings ($5.66B) actually sitting lower than 2021 levels. Operating margins have faced pressure, dropping as the company handles higher medical loss ratios and integration costs. Equity has grown steadily to $43.88B, but return on equity (ROE) is currently trending downward. The business model relies heavily on government contracts and employer-sponsored plans, where pricing power is often curtailed by regulatory oversight.
Major Opportunities
- Massive revenue scale exceeding $199B
- Strong market position in Blue Cross Blue Shield licenses
- Successful pivot to health services via Carelon
Major Risks
- Operating margins compressed to under 4% in 2025
- Cash flow from operations on a 3-year downward trajectory
- Increasing long-term debt levels exceeding $30B
Unlock the full report
Full 20+ sections, charts, AI chat with the report, and PDF export are available with Premium.